Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...
Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...
The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.
StarsInsider on MSN10d
The rare inflammatory condition that is sarcoidosisSarcoidosis is a rare inflammatory condition that develops when groups of cells in your immune system form patches of swollen ...
More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...
(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...
The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...
This new lung disease AI model gives us a clue as to what is yet to come, with it able to correctly identify nuances that differentiate, for example COVID-19 from pneumonia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback